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Abstract
 
  
 Lidocaine, a local anesthetic was encapsulated into zein nanofibers through 
electrospinning. The impact of process parameters on electrospinning was studied in this project.  
Differences on nanofiber morphology made by concentration of fiber forming solutions (20%, 
25%, 30%) type of solvent, voltage (10 kV, 12 kV, 13 kV, 15 kV and 17 kV), flow rate (0.3 
mL/h, 0.5 mL/h and 0.7 mL/h), and collecting distance (10 cm, 12 cm, 14 cm, 20 cm, 30 cm) on 
fiber morphology were examined. The optimal conditions for spinning were found to be 25% 
zein concentration, 70% ethanol: water (w/w), 15 kV voltage, flow rate of 0.3 mL/h, collecting 
distance of 10 cm, and 10 mL syringe with 0.80×22 mm needle tip, and the experiments were 
carried out in room temperature and 60% relative humidity. Various concentrations of the active 
pharmaceutical ingredient (API), lidocaine, were successfully loaded into the nanofiber. The 
presence and concentration of lidocaine in the nanofibers was determined through HPLC. The 
releasing behavior of the API was studied in vitro using PBS buffer followed by HPLC 
quantification, and in vivo by Skin Raman experiments. It was found that a fast and complete 
release of lidocaine from the nanofiber was achieved in PBS buffer (pH7.4) and released that 
lidocaine into the first 5 m of human skin depth as followed by Raman experiments. 
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1.0 Introduction
 
1.1 Electrospinning  
Electrospinning is one of the way to produce fibers with diameter ranges from tens to 
hundreds of nanometers using electric fields.[1] A syringe with polymer solution is set up on an 
infusion pump and connected to high voltage. When increasing the voltage and thus increasing 
the strength of the electrostatic field, the repulsive forces generated by the induced surface 
charges would overcome the surface tension of the solution, and cause a pendant drop at the tip 
of the needle to form a so called ‘Taylor cone’. Then the charged fiber jet would erupt from the 
tip forward to a grounded collector. During the process of eruption, solvent evaporates from the 
jet and left only fibers on the collector(Figure 1) [1]. Functional electrospun fibers have great 
potential in industrial use due to their ability of incorporating various additives such as active 
pharmaceutical ingredients (APIs), antioxidants, antibacterial ingredients, and others [2]. 
Electrospun fibers have a high surface-to-volume ratio, which makes them a good candidate for 
fast releasing system as they show strong interactions with surrounding materials.   
 
Figure 1: Schematic electrospinning setup for the production of zein protein fibers. 
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1.2 Zein  
 Zein is a class of prolamine protein, that is hydrophobic and can be extracted from corn. 
Zein is the storage protein of the corn, and is a mixture of proteins with various sizes and 
solubilities. Zein proteins are expressed during the developmental stage of the seed and act as 
storage for free amino acids [3].  This protein was classified into four structures: α, β, γ, and δ. α 
-Zein contributes to 70% of the four. Unlike the other three forms, it can only be extracted 
through aqueous alcohol. Most commercial zein products contain α -zein because the other three 
forms are easy to gelified. α-zein has two polypeptides, one is 19 kDa and another one is 22 kDa. 
Those two polypeptides were used in further experiments to determine whether the 
electrospinning process will interrupt the structure of zein or not. Zein can be dissolved in binary 
solvents with alcohol and water, such as aqueous ethanol [4]. 
 Using zein to produce fibers was first introduced by Ostenberg in 1919. It is widely used 
in the food and pharmaceutical industry due to its thermal resistance and oxygen barrier 
properties. It is often used in coating and packaging because it can form films. Meanwhile it’s 
biodegradable and renewable. [5] The first major commercial uses of zein was coating; it was 
used as a replacement of shellac in WWII, it can be used in floor coating in engine rooms of 
steamships because it’s durable and resistant to grease. More recently, zein has been used as a 
replacement for polyolefin as coating for paper in food industry since it was found that zein is 
efficient enough to act as a barrier in fast service packaging. In 1958, Winters and Deardorff 
found that zein can be used for coating tablets since the coating process is rapid due to its film 
forming ability. It is also resistant to microbes, heat and humidity[4]. 
The first use of zein in producing fibers was patented in 1919 by Ostenberg, but back 
then, people were using either dry spinning or wet spinning to produce the fibers. The methods 
have been improved by many scientists. Later in 1949, Evans found that fibers can also be 
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produced by a two-step method[4]. Zein is mostly the byproduct of ethanol production, although 
Zein has great potential for commercial use in various industries, its high cost has always the 
chief concern for years[6].  
Recently, zein was used in nanofiber production using the electrospinning process.[1] In 
that experiments, zein was dissolved in aqueous ethanol and used for production of nanofibers. 
Those fibers were used as a controlled drug release system. It was found that there are many 
parameters that can affect the morphology of the electrospun fibers during the process, such as 
concentration of fiber-forming solution, applied voltage, collecting distance, flow rate, etc.[1]. 
Based on the previous studies, one hypothesis was made that when other parameters are constant, 
higher voltage, smaller flow rate, longer collecting distance and higher concentration would give 
less beads on the fiber, and thus a nicer fiber.[1] Those parameters were tested in separate 
experiments and the morphology were measured by SEM.  
 
 
1.3 Lidocaine 
Lidocaine is a local amide anesthetic that is often used to treat ventricular tachycardia and 
blocks nerves, which can cause the side effects such as lower blood pressure. Lidocaine was first 
discovered by Nils Lofgren and Bengt Lundqvist in 1946 and became a commercial drug 2 years 
after its discovery. It is faster and safer than other older local anesthetics[7]. It can be used in 
surgical procedures such as oral surgery. When mixing with epinephrine, it can increase 
numbing effects and decrease bleeding. Lidocaine begins its effects within five minutes 
following the infiltration and can persist up to 3 hours[8]. In this study, lidocaine will be loaded 
into nanofibers by adding it to the fiber forming solution before electrospinning. Its releasing rate 
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will be monitored through a drug release profile. It is expected that by loading the drug onto the 
fiber, there would be changes on API’s releasing behavior such as releasing rate. The drug 
release profile of lidocaine in vitro was evaluated by Glavas-Dodov. The lidocaine was 
encapsulated into liposomes. Over 70% of lidocaine loaded were found to be released. The 
concentration of gelling agent had slight effects on releasing rate. The release kinetics were 
found to be controlled through releasing profile data.[9]   
 
 
1.4 Application of nanofibers in drug delivery for skin 
 Recently, nanofibers have been introduced to the public and attracted significant attention 
for their great potential in biomedical applications. They can be used for cell growth scaffolds, 
tissue engineering and drug delivery due to their high surface area. Various agents can also be 
incorporated into nanofiber such as anti-inflammatory, anti-microbial, antioxidant substances. 
This provides a wide range of applications of nanofibers in wound dressing, cosmetics and drug 
delivery. [10] 
 In this project, nanofibers were used as a controlled drug delivery system because of the 
entrapment of the drug inside the nanofiber. Electrospun fibers showed higher precision at the 
targeted site than other traditional methods. Meanwhile, the use of biodegradable material such 
as Zein is also beneficial for drug delivery. [10] Similar application can be found in the industry 
today such as Rivelin, a  self-adhesive oral drug patch that composed of electronspun nanofibers. 
This patch allows better interactions between mucosal surface and biodegradable layers, helping 
to treat oral diseases. [11] 
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1.5 Skin Raman Spectroscopy  
 
Raman spectroscopy is a noninvasive method to determine molecular concentration 
profiles inside skin. Raman spectroscopy is a vibrational spectroscopy technique that is based on 
inelastic scattering of light. It is possible by Raman microscopy to obtain information of 
molecules inside skin tissue down to hundreds of micrometers. The scattering of light is caused 
by the interaction between photons and molecular vibrations when samples are illuminated with 
monochromatic laser light. The amount of energy that is needed to excite a molecular vibration is 
missing in the back scattered signals which allows to obtain a vibrational spectrum of the excited 
molecules.  The Raman signal is collected as the laser focus is scanned across the skin and 
moved to different depths from the skin surface. Raman spectroscopy is widely used in 
biological, pharmaceutical, medical and cosmetic industry. Concentration of molecules such as 
NMF (natural moisturizing factors) in the stratum corneum, as well as other APIs can be 
determined by Raman spectroscopy[12]. 
 
1.6 Objective of this project   
 In this project, the potential of electrospun zein nanofibers to be used as a drug release 
system was analyzed. Zein was dissolved in aqueous ethanol in an optimal concentration, along 
with the active pharmaceutical ingredient, lidocaine, a local anesthetic. The solution was used in 
the electrospinning process to produce nanofibers with diameter ranges from tens to hundreds of 
nanometers. The API was trapped in the nanofibers and gradually released from the fiber. The 
drug releasing behavior including its rate was monitored in vitro, by dissolving nanofibers in 
PBS buffer of pH 7.4 and in vivo by skin Raman analysis.  The concentrations of the drug in the 
 11 
PBS were determined using HPLC. The nanofibers can be produced as patch, directly applied to 
skin after moisturizing. The content of lidocaine in skin was measured.  Once the efficiency of 
loading and releasing behavior has been studied, lidocaine-loaded biodegradable nanofibers can 
be used in commercial or medical practice, where lidocaine is one of the most widely used local 
anesthetics[13]. 
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2.0 Materials and Methods 
 
2.1 Materials 
  Zein powder was purchased from A.F. Suter & Co. Ltd, Essex, UK. It was used as 
received, without further purification. Lidocaine powder was purchased from Fagron Inc, MN, 
USA.  
 
2.2 Fiber-forming solution preparation  
 Different concentrations (20%, 25% and 30%) of fiber-forming solutions were prepared 
by weight. Zein powder was dissolved in aqueous ethanol solution (ethanol/water, 70 % w/w). 
The solutions were stirred in room temperature for one hour.  
 
 
2.3 Electrospinning  
 Fiber-forming solutions were placed in a 10 mL syringe with a 0.8*22 mm tip when the 
powder was fully dissolved. The syringe was set up on an infusion pump with different flow 
rates (0.3 mL/h, 0.5 mL/h and 0.7 mL/h). The needle tip was directly attached to the positive 
electrode of a high voltage direct current power supply. The optimal voltage was determined by 
using different voltage settings. (10 kV, 12 kV, 13 kV, 15 kV and 17 kV). As the charge built up 
at the needle tip where the solution was fed by the infusion pump, the zein solution was ejected 
toward the grounded collector plate which was placed at different distances (10 cm, 12 cm, 14 
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cm, 20 cm, 30 cm). During the ejection process, the solvent evaporated from the fiber jet. The 
fibers were then collected on an aluminum foil attached to the collector plate.  
 
 
2.4 Drug loading  
Lidocaine was loaded by adding it to the zein-only fiber forming solution before the 
electrospinning process. 25% zein-only fiber forming solution was first prepared as described 
above. Different amounts of lidocaine hydrochloride powder were then added to pre-stirred 25 % 
zein-only solution to form API loaded solution of different mass percent relatively to zein (4%, 
10 %, 20 % and 50%)(Table 1). 
Table 1:Preparation of lidocaine-loaded fiber forming solution 
Solutions Mass of 
lidocaine(mg) 
Mass of zein(g) Mass percentage 
to solution(%) 
Mass 
percentage(%) to 
zein 
4%-ZL 40 0.932 1.075 4.3 
10%-ZL 100 0.932 2.675 10.7 
20%-ZL 200 0.932 5.375 21.5 
50%-ZL 450 0.932 12.05 48.2 
 
 
The electrospinning process was carried out with the optimal parameters determined in 
previous experiments, which was 15-17 kV, 0.3 mL/h flow rate, and 10 cm collecting distance. 
Fiber containing lidocaine was collected on a plate wrapped with aluminum foil. 
 
2.5 Morphology of Fibers 
 A scanning electron microscope (SEM), Scientific Quanta FEG 250, Thermo Fisher 
Scientific, OR, USA, was used to examine the morphology of the electrospun fibers. The 
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samples were prepared by sputtering the fibers with gold nanoparticles. Images were taken from 
14 samples that were obtained using different fiber forming parameters. The diameters of 
nanofibers were measured using software ImageJ, a histogram was created using measurements 
collected from SEM images.  
 
2.6 Viscosity 
The viscosity of the polymer solutions was determined by a rotational viscometer 
Brookfield Digital Remoter Model DV-III, MA, USA. Four samples were measured to compare 
the possible impact of viscosity on fiber morphology. Three samples of 25% zein concentration 
with different lasting time and one 30 % zein concentration sample were measured. 
 
 
2.7 Fourier-transform infrared spectroscopy 
 The Fourier-transform infrared (FTIR) spectroscopy measurements were carried out 
using a Bruker Tensor 37 FTIR spectrometer, MA, USA. Electrospun fibers, zein powder and 
lidocaine powder were dissolved in ethanol and let dry.  
 
 
2.8 UV-Vis 
 UV-Vis spectra were determined using a SPECORD® S 600, Analytik Jena AG, Jena, 
Germany UV-Vis spectrometer. Zein powder and lidocaine were dissolved in methanol with the 
same concentration (10%); methanol was used as blank.  
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2.9 HPLC 
 High-performance liquid chromatography (HPLC) of the samples was performed using 
Agilent 1200 series instrument, CA, USA.  The separation was performed using a C18 
100mm*5mm column at room temperature (28 ℃) with 1 mL/min flow rate and an injection 
volume of 10 L. A 65:35 (v: v) 0.05 M sodium phosphate buffer: acetonitrile was used as 
mobile phase; sodium phosphate buffer was adjusted to pH 6 using sodium hydroxide. The 
wavelength detector was set to 210 nm. Lidocaine hydrochloride standard solutions were made 
by dissolving lidocaine hydrochloride in acetonitrile with different concentrations. 5 mg/L, 10 
mg/L, 15 mg/L, 20 mg/L and 25 mg/L standard solutions were analyzed and used to obtain a 
standard curve(Table 2).  Standard curves were calculated using the results from 4 trials. The 
standard equation was found to be y= 31.911x-57.131. The r- value was found to be 
0.999.(Figure 2) 
 
Table 2 Preparation of standard lidocaine solution 
Solutions Mass of 
lidocaine(mg) 
Volume of 
Acetonitrile(mL) 
Concentration(mg/L) 
Std-5 0.5 100 5 
Std-10 1.0 100 10 
Std-15 1.5 100 15 
Std-20 2.0 100 20 
Std-25 2.5 100 25 
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Figure 2: Standard curve for lidocaine concentration 
2.10 Optimization of Electrospinning 
 During the process of electrospinning, the tip of the syringe needle became clogged by 
the polymer due to ethanol evaporation. This required constant cleaning at the needle tip. To 
solve this, a 3D-printed coaxial nozzle was used to provide more ethanol vapor at the tip to 
decrease the speed of clogging. Nitrogen was pumped into ethanol and the needle was 
surrounded by the cooling ethanol vapor by coaxial nozzle(Figure 3). 
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Figure 3: Coaxial nozzle schematic setup for optimization of electrospinning process. A. Experimental set 
up for spinning process. B: Experimental ethanol vapor set up. C: 3D printing model for coaxial nozzle. 
D: Schematic setup. 
 
 
2.11 SDS-Page 
 The SDS-Page resolving gels were made of 4.8 mL acrylamide (30 % w/v)/bis-
acrylamide (0.8 % w/v) solution, 5 mL tris buffer (pH 8.8), 50uL 20 % SDS, 100 L 10 % APS, 
10 L tetramethylethylenediamine and 50 L water. The stacking gels were made of 1.5 mL 
acrylamide (30 % w/v)/bis-acrylamide (0.8 % w/v) solution, 2.55 mL Tris buffer (pH 8.8), 50 L 
20 % SDS, 100 l 10% APS, 10 L tetramethylethylenediamine and 5.85 mL water.  The 
resolving gel was poured between two glass plates and clipped together on a casting frame. 
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Bubbles were removed by the addition of isopropanol on the top of the gel. After the gel had 
gelified, the stacking gel was poured on top of resolving gel.  The wells were formed after 
placing comb in gel after pouring the stacking gel. The concentration of protein in each well was 
made to be 2 mg/mL. 15 g of samples was injected into each well making the final products 30 
g. The coloring buffer Coomassie was added to the gel for 1 hour and was washed off 
overnight. The ladder used was Dual Xtra.  
 
2.12 Drug Dissolution  
 The lidocaine containing electrospun fibers were placed in 100 mL PBS buffer (pH7.4) 
and 1 mL of solution was taken every one minute for the first five minutes, and every five 
minutes after the first five minutes for 4 hours under constant stirring. The fibers added to PBS 
buffer were weighted and the amount of lidocaine present in the fiber was calculated. The 
concentration of the lidocaine released in the buffer was measured by HPLC.  
A standard curve of lidocaine concentrations corresponding to the area on HPLC 
spectrum were built after the assay of 5 mg/L, 10 mg/L, 15 mg/L, 20 mg/L and 25 mg/L 
lidocaine standard solution as described above.  
Different concentration of lidocaine in PBS buffer were tested. 20mg of nanofiber 
containing lidocaine were weighted and placed in 100 mL PBS buffer(pH=7.4) under constant 
stirring, 1 mL of solution were collected every minute for the first five minutes and every five 
minutes afterwards for 30 minutes. The concentration of lidocaine in each sample were 
calculated using the standard equation. The mass of the lidocaine in each sample taken out and 
remaining in the buffer were then calculated by dividing their volumes. The amount of lidocaine 
taken out was added to the next releasing amount. The percentage of lidocaine released was then 
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calculated and plugged into the graph by dividing the original mass of lidocaine that was added. 
(Appendix A) 
 Then, 53 mg of nanofiber containing lidocaine were weighted and placed in 100 mL PBS 
buffer (pH=7.4), 1 mL of solution were taken out at 3 minutes and every 5 minutes for 1 hour 
and one sample was taken at 4 hours. Collected data were analyzed using the method described 
above. (Appendix B) 
2.13 Human Skin Raman Test 
The releasing behavior of lidocaine loaded fiber as a patch that was directly applied to 
skin after moisturizing was studied using Model 3510,RiverIcon 2.5 Skin Composition Analyzer, 
River Diagnostics, Rotterdam, Netherlands. 
 In this experiment, Raman spectroscopy was used to determine the presence of lidocaine 
in human skin after applying the patch containing nanofibers. Lidocaine and zein reference were 
prepared by dissolving 2 % lidocaine 70 % aqueous ethanol (w/w), and 10 % zein powder(w/w) 
in ethanol. A 1 cm2 patch with 2 mg nanofibers that contain 86 g lidocaine was applied to 
human skin on the inside of the wrist after moisturizing for five minutes using an allergy patch. 
Another patch with the same size containing 0.1 mg 25 % zein only nanofibers was also tested. 
The patches were removed after five minutes and the same areas of skin were analyzed. The 
Raman intensity of lidocaine relative to keratin, a protein that is commonly seen in human skin 
[14] was recorded. The Raman intensity of lidocaine in zein-only fiber was measured as blank 
and it was subtracted from the measurements of lidocaine-loaded fibers to obtain the Raman skin 
depth profile. Approximately 10 Raman depth profiles were taken at different positions, and 
averages were used in further analysis to account for the variability of skin at the microscopic 
level.     
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3.0 Results 
 
3.1 Impact of different parameters on nanofiber morphology 
 In order to study the impact of different parameters (fiber forming solution concentration, 
flow rate, voltage and collector distance) on nanofiber morphology, 10 samples with different 
production parameters were chosen and analyzed. (Table 3) 
Table 3 SEM image sample parameters 
Samples Zein 
Concentration 
(%) 
Collector 
Distance 
(cm) 
Voltage 
(kV) 
Flow rate 
(mL/h) 
Morphology/Average 
diameter size(nm) 
Z20-a 20 12 17 0.3 Fiber with beads, 
145.62 ±44.96 
Z20-b 20 12 17 0.5 Fiber with beads 
Z20-c 20 12 17 0.7 Fiber with beads 
Z20-d 20 12 13 0.3 Fiber with beads 
Z20-e 20 12 15 0.3 Fiber with beads 
Z20-f 20 10 17 0.3 Fiber with beads 
Z20-g 20 14 17 0.3 Fiber with beads 
Z25-a 25 12 15 0.3 Fiber without 
beads,364.01±113.22 
Z30-a 30 12 15 0.3 Fiber without 
beads,612.49±156.55 
Z30-b 30 20 15 0.3 Fiber without beads 
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3.1.1 Impact of differences in flow rate 
 
 Flow rate for the electrospinning process is one of the parameters that may play a role in 
the production of different fiber morphologies. In this experiment, the concentration of fiber 
forming solution, voltage and distance of collector from needle tip were kept constant for 20 % 
zein concentration with 70 % aqueous ethanol solution (w/w), 17 kV and 12 cm. A flow rate of 
0.3 mL/h was determined to give fibers with less beads, and thus better results compared to 
0.5mL/h and 0.7 mL/h flow rates(Figure 4). 0.3mL/h was then used as fixed parameter in further 
experiments to determine other optimal parameter conditions. 
 
Figure 4: SEM images of zein nanofibers produced with different flow rate. a:0.3mL/h, b:0.5mL/h, 
c:0.7ml/h. 
3.1.2 Impact of differences in electric field 
 The applied voltage in the electrospinning process is another parameter that is been 
studied in this experiment. Zein protein fibers forming solution were prepared with 20% Zein 
concentration in a 70% aqueous ethanol solution(w/w).  The concentration of the solution, flow 
rate and distance of the collector from the needle tip were kept constant. The flow rate used in 
this experiment was 0.3mL/h, the distance was 12 cm. Differences in the morphologies of fibers 
using 13kV, 15kV and 17kV were examined using SEM. All three fibers showed many beads 
inside the fibers and with relatively the same diameter size ranging from 100-200 nm (Figure 5). 
Therefore, different collecting distances were then examined.  
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Figure 5: SEM images of nanofibers produced with different electrical field.d:13kV,e:15kV,a:17kV. 
 
3.1.3 Impact of collector distance 
 In this experiment, voltage, flow rate and concentration of the solution were kept constant 
as in previous experiments. The parameters are 17kV, 0.3mL/h and 20% zein concentration with 
70% aqueous ethanol solution(w/w). Three different distances were measured, 10 cm, 12 cm and 
14 cm. Like it was observed for the experiments with varying voltages, the differences in 
distance did not provide much different fibers. There are beads observed inside fibers in all 
cases. The approximate diameter size ranged from 80-250 nm (Figure 6). After all three 
parameters have been examined, no obvious differences were observed in terms of reducing the 
number of beads. Therefore, another hypothesis was made that increasing the concentration of 
zein in solution will decrease the number of beads and increase the fiber size when other 
parameters are constant.  
 
Figure 6: SEM images of zein nanofibers produced with different collector 
distance.f:10cm,a:12cm,g:14cm. 
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3.1.4 Impact of fiber forming solution concentration  
 Three different concentrations of zein protein in 70 % aqueous ethanol solution (w/w) 
were tested. The flow rate was fixed to be 0.3 mL/h, the voltage was 15 kV and the collecting 
distance was 12cm. Solutions with concentration of 25 % and 30 % zein showed significant 
improvement in reducing the number of beads. Very little beads were observed on those 
fibers(Figure 5). Meanwhile, solution with 30% concentration produced fibers with larger 
diameter, ranging from 400-750 nm, whereas a concentration of 25% yielded a fiber diameter 
size ranging from 150-350 nm. 30 % Zein solution with 20 cm collecting distance also showed 
decrease in fiber diameter compare to the experiments with 10 cm collection distance (Figure 7-
10).  
 
 
Figure 7: SEM images of zein nanofibers produced with different fiber forming solution concentration.  
 
 
Table 4 Viscosity of the Zein Solution 
Sample Viscosity  
25% Zein with 70% Ethanol/water (w/w) (day 1) 93.51±0.29 
30% Zein with 70% Ethanol/water (w/w) (day 1) 206.21±0.61 
 
As the concentration of zein increased, the viscosity of fiber-forming solution increased. 
The viscosity also depends on the temperature of the measuring time. The 25 % solutions were 
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prepared and measured three times on different days. The viscosity measurements clearly 
showed changes in the values throughout the time course of the experiment (Table 4). 
Nanofibers with 30% Zein concentration showed larger diameter size in SEM images, suggesting 
that higher viscosity could lead to production of nanofibers with larger diameter size. (Figure 8-
10)  
 
 
 
 
3.2 Impact of different parameters on nanofiber diameter size range 
Three samples, Z20-e, Z25-a and Z30-a were chosen and 100 measurements of diameter on 
SEM nanofiber images were taken through ImageJ. Based on the measurements, a histogram of 
diameter size ranges was obtained (see Figure 8-10). 
 
 
Figure 8: Diameter size range for zein nanofibers with 20 % concentration. The diameters ranged from 
100-300 nm. 
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Figure 9: Diameter size range for zein nanofibers with 25 % concentration. The diameters ranged from 
around 200-700 nm. 
 
Figure 10: Diameter size range for zein nanofibers with 30 % concentration. The diameters ranged from 
400-900 nm. 
 
The histograms of three samples, Z20-e, Z25-a and Z30-a showed that, as the concentration 
of zein in nanofiber forming solution increased, the approximate diameter size also increased. 
The 20 % zein concentration solution generally produced fibers with diameters of 100nm to 200 
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nm, whereas 30% zein concertation nanofibers forming solution produced fibers with diameters 
from 400 nm to 900 nm. 
 
3.3 Morphology of lidocaine-loaded nanofibers 
 Three different amounts of lidocaine (10%, 25 %, and 50 % relative to zein) were then 
added to 25 % zein fiber-forming solution and mixed well. Fibers were produced under optimal 
conditions determined in the previous experiments, which was 15 kV, 0.3 mL/h flow rate, 10cm 
collecting distance and 0.8*22 mm needle tip. All fibers showed similar diameter sizes, ranging 
from 200 nm to 500 nm, no obvious beads were observed in the SEM images(Figure 11). Thus, 
the morphology of the nanofiber was not influenced by loading of drug.  
 
Figure 11: SEM images of lidocaine-loaded electrospun zein nanofiber with flow rate of 0.3mL/h, 15kV, 
25% Zein concentration with different amount of lidocaine relative to zein. A: 10% lidocaine; B: 20%; C: 
50%. All fibers showed approximately same diameter ranged from 200nm-500nm. 
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3.5 Presence of lidocaine in nanofiber (HPLC) 
 The presence of lidocaine in the respective nanofibers was tested using high-performance liquid 
chromatography (HPLC). A standard HPLC method for determination of lidocaine was developed using 
known concentrations from 5 mg/L to 25 mg/L; 70% methanol to 30% water (w: w) was used for these 
experiments. Electrospun fibers using fiber forming solutions containing lidocaine were dissolved in 
ethanol and assayed using HPLC. Lidocaine shows a strong absorbance at a wavelength of 195 nm, and 
elutes between 1 to 2 minutes. After testing the fiber samples, a standard lidocaine solution of 25 mg/L 
was added to the original sample. Same peak showed on spectrum with lowered intensity, indicating the 
lidocaine was successfully loaded to the fiber with concentration higher than 25 mg/L. The area under the 
peak of the fiber-only sample was 1427, after diluting the sample with standard lidocaine solution, the 
area under the peak decreased to 968 (mAU*s) (Figure 12.).The concentration of lidocaine in electrospun 
fiber is found to be 91.119mg/L by plugging the area into the standard curve. After being diluted with 
standard lidocaine solution, the final concentration of sample with both fibers and standard solution was 
found to be 61.725 mg/L. 
 
Figure 12: High-performance liquid chromatography (HPLC) results of lidocaine-loaded fiber/fiber with 
standard solution. A: lidocaine-loaded fiber dissolved in ethanol; B: lidocaine-loaded fiber dissolved in 
ethanol, diluted with 25mg/L lidocaine standard solution. Lidocaine eluted around 1.5 min, the intensity 
of the peak changed after addition of standard solution, indicating lidocaine is present in the fiber, absorbs 
at 195nm. 
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Fourier-transform infrared spectroscopy and UV-Vis spectroscopy 
 The presence of lidocaine in the nanofiber was also studied using Fourier-transform 
infrared spectroscopy (FTIR) and UV-Vis spectroscopy. However, both methods showed very 
little difference to sufficiently prove that lidocaine was loaded onto the fiber(Figure 13). 
 
Figure 13: UV-Vis spectrum of lidocaine/zein. The dissolved zein sample was represented by orange line 
and lidocaine sample was represented by the blue line. 
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3.6 SDS-page 
  
Figure 14: SDS-Page of electrospun fiber. Sample 1: 25% zein fiber without lidocaine; Sample 2: 4% 
lidocaine-loaded 25% zein fiber. Sample 3: 50% lidocaine loaded 25% zein fiber. Control: zein powder 
dissolved in ethanol. All samples shoed bands at 19kDa and 22kDa. 
The electrospun fibers were observed to be ivory, since the zein powder has yellow-orange color. 
It was investigated whether the electrospinning process could break the structure of zein. Thus, 
an SDS-page gel electrophoresis experiment was performed on the fiber to determine whether 
the protein is still complete. The α-zein contains two polypeptides: 19 kDa and 22 kDa [1], 
which was shown by the SDS-page gel results (Figure 14). Therefore, the α-zein was still present 
after the electrospinning process.  
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3.7 Drug Dissolution  
  0.858 mg lidocaine was released in PBS buffer at 100% in the first five minutes, the 
released percentage was 96% at 3 minutes. (Figure 15) 
 
Figure 15: Releasing profile of 0.858mg-lidocaine loaded fiber in PBS buffer 
Since the lidocaine was released 100% in the first 5 minutes, samples with more lidocaine 
concentration and shorter collecting intervals were examined. The release profile was built using 
the same method. This dissolution showed a fast and complete drug release at 1 minute. (Figure 
16).  
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Figure 16: Releasing profile of 2.82mg-lidocaine loaded fiber in PBS buffer. 
 
 
3. 8 Skin Raman Test 
2% lidocaine aqueous ethanol solution and 10 % Zein solution were used as reference. 
Zein-only fiber patch was applied to human skin after moisturizing the skin for 5 minutes, the 
amount of lidocaine in skin was measured and recorded. The data were analyzed using keratin as 
reference, a protein that can be found in human skin. The measurement of lidocaine in skin at 10 
different positions with different depths in skin were recorded (Appendix C) and plugged into a 
profile and used as blank. (Appendix D).   
 After obtaining the relative lidocaine amount in skin after applying zein-only fiber patch 
as blank, measurements of lidocaine in skin after applying a Zein-lidocaine fiber patch were 
recorded (Appendix E) and analyzed (Appendix F). 
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The two skin depth profile were then combined and compared (Appendix G). A drug 
profile was obtained by subtracting zein-only profile (blank) from lidocaine loaded profile 
(Figure 17).  The drug profile showed that there was evidence of lidocaine present in the first 
5m in skin depth. Although the releasing efficiency needs further studies, these experiments 
proved that 4% lidocaine encapsulated in zein nanofiber was able to release in vivo by directly 
applying as a patch after moisturizing the skin.  
 
Figure 17 : In vivo skin depth lidocaine profile after applying zein-lidocaine patch for five minutes. 
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4.0 Discussion 
 
Lidocaine was successfully encapsulated into nanofibers, and in vitro releasing profiles in 
PBS showed high efficiency in loading and releasing API’s. It is a fast and complete release in 
the first minute.  This patch can be used as an instant anesthetics product. The next step could be 
decreasing its releasing rate so it can have a greater potential in pharmaceutical industries as a 
long-term painkiller. Other APIs such as ibuprofen were successfully added to zein 
electrospinning nanofibers and showed sustained drug release through In vitro dissolution tests 
by Huang and his group. They also used  modified coaxial electrospinning process to preventing 
clogging. Unelectrospinnable solvent, DMF, was used as sheath fluid. [15] 
The presence of lidocaine was determined by HPLC and there is no obvious change in 
the morphology of the fibers based upon the SEM images. The in vivo release profiles were 
studied through Raman skin test on human skin. Lidocaine was found in skin by directly 
applying patches containing nanofibers after moisturizing. Further studies are needed for the in 
vivo skin test for quantification. 
In regards to the electrospinning process, all samples with 20% zein concentration have 
beads inside the fiber. 25% zein solution and 30% solution gave fibers without beads. Due to the 
higher concentration, the 30% zein solution produced thicker fibers with diameters ranging from 
400 nm to 750 nm. 25% zein solution produced fibers with diameters ranging from 150 nm to 
350 nm. Longer collecting distances also result in decreasing fiber diameter sizes. Although 
there is no direct evidence showing the correlation between viscosity and fiber morphology, it is 
hypothesized that increasing viscosity may lead to larger diameters, since the comparison of the 
average fiber diameter size for 30% and 25% zein fiber showed larger diameters for the higher 
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zein concentration. By adding a coaxial nozzle, the time that the tip was clogged was elongated 
from 10-15 seconds up to around 120 seconds. Although the clogging issue was not completely 
solved, decreasing the surrounding temperature and providing more solvent improved the 
electrospinning process. More modifications can be done on this apparatus to achieve better 
results in the future including introducing a poor volatile organic solvent as a sheath fluid as Yu 
et al reported.[16] 
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Appendix A: Releasing data of 0.858 mg-lidocaine loaded fiber 
Time(min) Area 
Concentratio
n(mg/L) 
Mass of 
lidocaine in 
buffer(mg) 
Mass of 
lidocaine 
taken 
out(mg) 
Mass of 
lidocaine 
released(mg
) 
Percentage 
0.00 0.00 0.00 0.00 0.00 0.00 0.00% 
1.00 243.30 9.41 0.94 0.01 0.94 109.73% 
2.00 231.54 9.05 0.90 0.01 0.90 105.48% 
3.00 257.79 9.87 0.97 0.01 0.99 114.87% 
4.00 286.71 10.78 1.05 0.01 1.07 125.12% 
5.00 260.47 9.95 0.96 0.01 0.99 115.92% 
10.00 267.19 10.16 0.97 0.01 1.01 118.25% 
15.00 269.16 10.23 0.96 0.01 1.02 118.93% 
20.00 282.91 10.66 0.99 0.01 1.06 123.59% 
25.00 287.33 10.79 0.99 0.01 1.07 125.08% 
30.00 278.60 10.52 0.96 0.01 1.05 122.18% 
180.00 297.42 11.11 1.00 0.01 1.10 128.37% 
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Appendix B: Releasing Data of 2.282mg-Lidocaine Loaded Fiber 
Time(min) Area Concentration
(mg/L) 
Mass of 
lidocaine in 
buffer(mg) 
Mass of 
lidocaine 
taken out(mg) 
Mass of 
lidocaine 
released(mg) 
Percentage 
(%) 
0.00 0.00 0.00 0.00 0.00 0.00 0.00 
3.00 641.51 21.89 2.19 0.02 2.19 95.94 
5.00 701.03 23.76 2.35 0.02 2.37 104.03 
10.00 723.98 24.48 2.40 0.02 2.44 107.12 
15.00 738.57 24.93 2.42 0.02 2.49 109.06 
20.00 764.47 25.75 2.47 0.03 2.57 112.48 
25.00 723.80 24.47 2.32 0.02 2.45 107.17 
30.00 758.30 25.55 2.40 0.03 2.55 111.63 
35.00 749.28 25.27 2.35 0.03 2.52 110.47 
40.00 760.39 25.62 2.36 0.03 2.55 111.88 
45.00 728.30 24.61 2.24 0.02 2.46 107.87 
50.00 751.00 25.32 2.28 0.03 2.53 110.67 
55.00 692.82 23.50 2.09 0.02 2.34 102.60 
60.00 757.82 25.54 2.25 0.03 2.50 109.42 
70.00 766.27 25.80 2.24 0.03 2.50 109.35 
280.00 714.26 24.17 2.08 0.02 2.33 102.12 
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Appendix C: Raman spectroscopy data of lidocaine in zein-only fiber(blank) 
Depth(mi
cron) 
Position 
1 
Position 
2 
Position 
3 
Position 
4 
Position 
5 
Position 
6 
Position 
7 
Position 
8 
Position 
9 
Position 
10 
Mean Value Standard 
deviation 
-10  8.00E+0
2 
1.05E+0
3 
-
1.09E+0
1 
6.11E+0
2 
1.46E+0
3 
3.74E+0
2 
1.63E+0
2 
1.16E+0
3 
5.36E+0
2 
 7.01E+0
2 
5.11E+0
2 
-8  2.09E+0
2 
1.11E+0
3 
-
8.03E+0
0 
6.12E+0
2 
2.43E+0
2 
5.52E+0
2 
3.22E+0
2 
9.95E+0
2 
7.01E+0
2 
 5.05E+0
2 
3.92E+0
2 
-6 2.36E+0
2 
2.87E+0
1 
5.30E+0
2 
2.33E+0
2 
4.70E+0
2 
3.67E+0
2 
522.4 4.70E+0
2 
6.73E+0
2 
6.02E+0
2 
-
1.22E+0
2 
3.92E+0
2 
1.97E+0
2 
-4 -
1.10E+0
2 
1.63E+0
2 
3.80E+0
2 
2.97E+0
2 
4.71E+0
1 
4.09E+0
2 
349.14 1.14E+0
2 
5.04E+0
2 
2.60E+0
2 
6.13E+0
1 
2.39E+0
2 
1.98E+0
2 
-2 130.13 180.27 1.51E+0
2 
291.02 125.04 2.29E+0
2 
246.24 86.109 2.82E+0
2 
217.09 108.64 1.91E+0
2 
7.37E+0
1 
0 168.14 93.434 97.91 158.48 50.469 119.38 101.61 -60.456 192.4 60.103 4.2592 1.02E+0
2 
7.51E+0
1 
2 -30.533 19.71 27.927 47.443 -34.707 39.691 -24.003 -91.349 59.792 97.055 -43.284 1.55E+0
0 
4.95E+0
1 
4 -139.2 8.8829 -35.41 22.312 -131.52 -40.097 44.928 -162.49 11.011 94.544 -20.831 -
4.68E+0
1 
7.82E+0
1 
6 -110.98 92.725 -15.333 35.448 -148.28 -70.514 52.122 -218.19 170.75 -69.16 63.007 -
2.36E+0
1 
1.24E+0
2 
8 44.678 130.07 15.281 85.669 -70.733 -65.145 86.393 -61.956 160.59 87.562 65.659 3.61E+0
1 
8.74E+0
1 
10 73.05 180.87 89.19 183.96 -25.932 27.349 90.432 -20.686 17.544 172.61 145.45 6.84E+0
1 
7.75E+0
1 
12 223.18 217.55 138.59 177.31 40.972 46.745 96.556 127.98 41.531 179.13 243.07 1.23E+0
2 
7.25E+0
1 
14 256.26 214.86 146.4 163.24 158.66 58.067 127.98 213.23 158.93 226.61 283.24 1.66E+0
2 
5.74E+0
1 
16 227.32 179.3 159.02 182.01 200.28 98.452 119.51 283.9 260.42 288.12 339.19 1.90E+0
2 
6.10E+0
1 
18 201.18 199.91 194.12 191.46 197.25 203 163.43 238.25 318.97 236.42 244.45 2.12E+0
2 
4.44E+0
1 
20 81.152 191.99 167.72 239.46 164.27 300.68 246.08 214.86 310.14 225.54 196.6 2.13E+0
2 
7.17E+0
1 
22 83.543 179.41 73.072 241.84 139.9 394.04 301.98 248.72 247.27 302.82 165.33 2.12E+0
2 
1.04E+0
2 
24 129.38 159.98 15.066 194.82 132.24 385.57 338.11 275.66 230.81 370.26 172.31 2.07E+0
2 
1.15E+0
2 
26 201.37 128.37 99.141 165.04 126.44 354.76 341.94 284.84 251.56 250.65 136.7 2.17E+0
2 
9.57E+0
1 
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Appendix D: In vivo Skin Depth profile of lidocaine in zein-only fiber(blank) 
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Appendix E: Raman Spectroscopy Data of Zein-lidocaine Fiber 
Depth(micr
on) 
Position 1 Position 2 Position 3 Position 4 Position 5 Position 6 Position 7 Position 8 Position 9 Mean 
value 
Standard 
deviation 
-10   7.33E+02 4.75E+02 1.59E+03 1.25E+03 4.26E+02   8.94E+02 5.07E+02 
-8  4.56E+02 3.62E+02 2.89E+02 3.80E+02 9.43E+02 3.35E+02 -
1.77E+02 
 3.70E+02 3.27E+02 
-6 2.68E+02 -
2.82E+01 
7.00E+02 4.79E+02 5.83E+02 8.82E+02 1.83E+02 -
2.33E+02 
1.20E+02 3.28E+02 3.61E+02 
-4 6.41E+02 2.31E+02 4.48E+02 5.13E+02 6.82E+02 4.80E+02 6.79E+02 1.15E+03 4.34E+02 5.84E+02 2.56E+02 
-2 646.2 392.3 417.03 374.92 383.25 288.74 659.93 8.74E+02 1.73E+02 4.68E+02 2.17E+02 
0 501.59 197.33 295.84 264.03 196.43 183.58 445.82 651.8 315.84 3.39E+02 1.61E+02 
2 182.14 -10.421 54.741 113.44 84.483 143.51 291.81 355.04 178.55 1.55E+02 1.14E+02 
4 -66.666 -110.29 -1.5984 35.693 -57.589 155.74 105.48 28.384 46.315 1.51E+01 8.48E+01 
6 -111.08 -214.58 16.527 18.235 -101.66 152.63 -0.75489 -229.18 -84.434 -
6.16E+01 
1.22E+02 
8 -121.79 -135 -0.61531 102.21 -29.806 116.44 3.0971 -176.74 -157.49 -
4.44E+01 
1.10E+02 
10 -110.82 -132.5 46.886 242.92 44.518 173.45 101.2 -138.29 -159.94 7.49E+00 1.49E+02 
12 -50.422 -53.39 128.31 248.14 131.83 288.26 188.17 -45.135 -92.807 8.26E+01 1.45E+02 
14 21.892 57.821 228.32 295.78 199.97 288.78 253.61 -67.685 27.995 1.45E+02 1.35E+02 
16 123.55 191.24 285.43 356.56 251.15 335.45 265.97 46.811 146.75 2.23E+02 1.03E+02 
18 208.48 299.44 254.7 336.23 246.31 325.46 277.78 186.64 221.38 2.62E+02 5.21E+01 
20 238.35 255.34 227.73 350.2 189.02 314.05 300.93 308.06 206.45 2.66E+02 5.50E+01 
22 226.44 218.35 238.34 324.47 136.63 247.37 275 370.86 260.9 2.55E+02 6.63E+01 
24 203.8 206 225.34 251.2 102.14 181.93 273.6 344.23 260.61 2.28E+02 6.73E+01 
26 181.51 210.99 171.25 195.93 85.03 164.18 294.41 284.98 218.3 2.01E+02 6.35E+01 
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Appendix F: In vivo Skin Depth profile of lidocaine in lidocaine loaded fiber 
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Appendix G:  In vivo skin depth profile of zein only and lidocaine loaded fiber 
 
 
 
 
